Squamous Cell Carcinoma Clinical Trials
Here are the 6 most popular medical studies for squamous cell carcinoma
Platinum-based Chemotherapy
Chemotherapy + Immunotherapy Before Surgery for Head and Neck Cancer
This trial is testing a chemotherapy regimen to see if it can effectively treat squamous cell carcinoma of the head and neck while also reducing side effects.
Popular filter options for squamous cell carcinoma trials
SCC Clinical Trials
View 56 SCC medical studies.
PARP Inhibitor
Pembrolizumab + Olaparib for Head and Neck Cancer
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
Head And Neck Squamous Cell Carcinoma Clinical Trials
View 55 Head and Neck Squamous Cell Carcinoma medical studies.
Platinum-based Chemotherapy
CACTUX for Head and Neck Cancer
This trial is testing a new cancer treatment called CACTUX. It's a combination of 3 drugs, and the investigators want to see if it's effective and has fewer side effects than the standard treatment.
Monoclonal Antibodies
Cetuximab + Interleukin-12 for Head and Neck Cancer
This trial is testing the side effects and best dose of a combination of two drugs to treat patients with head and neck squamous cell carcinoma that has come back or spread. The two drugs are recombinant interleukin-12 and cetuximab.
Metastatic Squamous Cell Carcinoma Clinical Trials
View 99 metastatic squamous cell carcinoma medical studies.
PARP Inhibitor
Pembrolizumab + Olaparib for Head and Neck Cancer
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
Alkylating agents
Mitomycin C for Head and Neck Cancer
This trial is testing whether mitomycin C will be effective in treating patients with incurable head and neck squamous cell carcinoma who have progressed after treatment with platin, 5-FU, cetuximab, and taxane.
P16 Positive Clinical Trials
View 15 p16 positive medical studies.
PARP Inhibitor
Pembrolizumab + Olaparib for Head and Neck Cancer
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
Alkylating agents
Mitomycin C for Head and Neck Cancer
This trial is testing whether mitomycin C will be effective in treating patients with incurable head and neck squamous cell carcinoma who have progressed after treatment with platin, 5-FU, cetuximab, and taxane.
Palbociclib + Chemoradiation for Head and Neck Cancer
This trial is testing a new cancer treatment that involves taking a drug called palbociclib before and after chemoradiation, to see if it improves outcomes for people with HPV-unrelated head and neck squamous cell carcinoma.
PD-L1 Positive Clinical Trials
View 10 PD-L1 positive medical studies.
PD-1 Inhibitor
Pembrolizumab + Anti-platelet Therapy for Head and Neck Cancer
This trial is testing a new cancer treatment combining two existing therapies in the hopes of creating a more favorable immunologic response in patients with a specific type of head and neck cancer.
Monoclonal Antibodies
Pembrolizumab + Radiation vs Chemotherapy + Radiation for Head and Neck Cancer
This trial is testing pembrolizumab, a monoclonal antibody, in combination with radiation therapy or pembrolizumab alone compared to the usual approach of chemotherapy plus radiation therapy after surgery in treating patients with head and neck squamous cell carcinoma that has come back or patients with a second head and neck cancer that is not from metastasis.
Phase 3 Squamous Cell Carcinoma Clinical Trials
View 99 phase 3 squamous cell carcinoma medical studies.
Immune Response Modifier
Imiquimod Cream for Basal Cell Carcinoma
This trial will compare Imiquimod vs. placebo cream for preventing basal cell carcinoma of the skin on the face. 1630 Veterans at high risk of BCC will be recruited from 17 VA medical centers.
Alkylating agents
Chemotherapy + Bevacizumab for Head and Neck Cancers
This trial is testing chemotherapy with or without bevacizumab to see how well it works in treating patients with head and neck squamous cell carcinoma that has come back or spread to other parts of the body.
Squamous Cell Carcinoma Clinical Trials With No Placebo
View 99 squamous cell carcinoma medical studies that do not have a placebo group.
PARP Inhibitor
Pembrolizumab + Olaparib for Head and Neck Cancer
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
View More Squamous Cell Carcinoma Trials
See another 68 medical studies focused on squamous cell carcinoma.
Frequently Asked Questions
Introduction to squamous cell carcinoma
What are the top hospitals conducting squamous cell carcinoma research?
Hospitals at the forefront of squamous cell carcinoma research are making significant strides in understanding and treating this form of cancer. In Saint Louis, the Washington University School of Medicine is leading the charge with 11 active clinical trials dedicated to squamous cell carcinoma. While they have only conducted one trial historically, their commitment since recording their first study in 2007 demonstrates a promising future for patients battling this disease. The Memorial Sloan Kettering Cancer Center in New york has also made notable contributions, currently undertaking five ongoing clinical trials and having completed seven previous trials focusing on squamous cell carcinoma since launching their initial investigation in 2007.
Meanwhile, in Houston's esteemed University of Texas MD Anderson Cancer Center, researchers are actively conducting four clinical trials aimed at better understanding and combating squamous cell carcinoma. Despite having just two previous studies under their belt since embarking on this research path back in 2004, the institution's dedication is evident as they continue to explore new treatment options for patients affected by this condition.
Further emphasizing the importance of these efforts is Boston's Dana Farber Cancer Institute where another four current squamous cell carcinoma clinical trials are underway alongside four completed studies dating back to their inaugural trial in 2006—a testament to their continuous pursuit of innovation within oncology research.
Rounding out our list is Charleston's Medical University of South carolina, which may have fewer active and historical clinical trials compared to its counterparts but still plays a crucial role. With three ongoing studies focused on squamous cell carcinoma and one past trial recorded from as recently as 2006, they contribute valuable insights into improving patient outcomes and expanding our knowledge about this particular type of cancer.
These top hospitals exemplify unwavering dedication toward unraveling the mysteries surrounding squamous cell carcinoma; each step taken brings us closer to more effective treatments that can improve lives and ultimately defeat this formidable foe.
Which are the best cities for squamous cell carcinoma clinical trials?
When it comes to squamous cell carcinoma clinical trials, several cities emerge as prominent hubs for research and development. New york leads the pack with 25 active studies exploring treatments like Cemiplimab, Definitive Hypofractionation, and Pembrolizumab 200 mg. Saint Louis closely follows with 22 ongoing trials investigating interventions such as Palbociclib, Pembrolizumab, and Pyrimethamine. Boston also plays a significant role in this field with 17 active studies focusing on therapies like Pembrolizumab and Cemiplimab. Additionally, Houston (16 trials) and Los Angeles (14 trials) contribute to the advancement of knowledge through their respective investigations into potential treatment options for squamous cell carcinoma.
Which are the top treatments for squamous cell carcinoma being explored in clinical trials?
In the realm of squamous cell carcinoma, clinical trials are exploring various treatment options that show promise. Leading the pack is pembrolizumab, currently involved in nine active trials dedicated to this specific type of cancer. Since its first listing in 2014, it has demonstrated potential through eight all-time squamous cell carcinoma trials. Alongside pembrolizumab, durvalumab has caught researchers' attention with three ongoing trials and one all-time trial since being introduced just last year in 2020. Additionally, cetuximab exhibits significant potential with three active and nine all-time squamous cell carcinoma trials since its debut back in 2008. These treatments provide hope for patients battling squamous cell carcinoma as research progresses towards finding more effective solutions to combat this disease.
What are the most recent clinical trials for squamous cell carcinoma?
Recent clinical trials for squamous cell carcinoma offer new hope and potential treatment options for patients. These trials include the evaluation of INCB099280 Dose 1, which has entered Phase 2 and shows promise in combating this type of cancer. Additionally, a combination therapy involving GB1211 and Pembrolizumab is being studied to assess its effectiveness against squamous cell carcinoma. The Reduce Dose without Concurrent Chemotherapy Rapid Responder trial aims to determine if reducing the dose of chemotherapy while maintaining efficacy can benefit patients with this condition. Other ongoing studies such as Single Cohort and Arm 1 are also exploring innovative approaches to better understand and treat squamous cell carcinoma. These advancements highlight the commitment of researchers towards improving outcomes for individuals affected by this disease.
What squamous cell carcinoma clinical trials were recently completed?
A recent completion of a clinical trial brings encouraging news for patients with squamous cell carcinoma. The University of Arizona led an investigation into the efficacy of injecting TVEC directly into target lesions during weeks 1-2. This ground-breaking trial, completed in August 2018, highlights the ongoing efforts to improve treatment options and outcomes for individuals battling this particular type of skin cancer. Though more research is needed, such advancements offer hope and potential breakthroughs in the fight against squamous cell carcinoma.